Targeting mitochondria by olesoxime or complement 1q binding protein as a novel management for autism: A hypothesis

Molecular Syndromology

Volumn 2, Issue 1, 2011, Pages 50-52

  Ghanizadeh, A ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Autism; Complement; Mitochondria; Permeability transition pore; Treatment

Indexed keywords

ADENOSINE TRIPHOSPHATE; BINDING PROTEIN; COMPLEMENT 1Q BINDING PROTEIN; COMPLEMENT COMPONENT C1Q; CYCLOPHILIN D; GLUTAMIC ACID; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT; NITRIC OXIDE; OLESOXIME; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; AUTISM; CELL DEATH; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EXCITOTOXICITY; HUMAN; HYPOTHESIS; MITOCHONDRION; NEUROPROTECTION; NEUROTOXICITY; OXIDATIVE STRESS; PRIORITY JOURNAL;

EID: 83055193604     PISSN: 16618769     EISSN: 16618777     Source Type: Journal    
DOI: 10.1159/000332202     Document Type: Article

References (23)

1. Bordet T, Berna P, Abitbol J-L, Pruss RM: Olesoxime (TRO19622): A novel mitochondrialtargeted neuroprotective compound. Pharmaceuticals 3: 345-368 (2010).
2. Brorson JR, Schumacker PT, Zhang H: Nitric oxide acutely inhibits neuronal energy production. The Committees on Neurobiology and Cell Physiology. J Neurosci 19: 147-158 (1999). (Pubitemid 29028957)
3. Chauhan A, Chauhan V: Oxidative stress in autism. Pathophysiology 13: 171-181 (2006).
4. Clementi E, Brown GC, Feelisch M, Moncada S: Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc Natl Acad Sci USA 95: 7631-7636 (1998). (Pubitemid 28293304)
5. Ghanizadeh A: Methionine sulfoximine may improve inflammation in autism, a novel hypothesized treatment for autism. Arch Med Res 4: 651-652 (2010a).
6. Ghanizadeh A: Targeting neurotensin as a potential novel approach for the treatment of autism. J Neuroinflammation 7: 58 (2010b).
7. Ghanizadeh A: Nuclear factor kappa B may increase insight into the management of neuroinflammation and excitotoxicity in autism. Expert Opin Ther Targets 15: 781-783 (2011a).
8. Ghanizadeh A: Oxidative stress may mediate association of stereotypy and immunity in autism, a novel explanation with clinical and research implications. J Neuroimmunol 232: 194-195 (2011b).
9. Ghanizadeh A: Targeting of glycine site on NMDA receptor as a possible new strategy for autism treatment. Neurochem Res 36: 922-923 (2011c).
10. Harada M, Taki MM, Nose A, Kubo H, Mori K, et al: Non-invasive evaluation of the GABAergic/ glutamatergic system in autistic patients observed by MEGA-editing proton MR spectroscopy using a clinical 3 tesla instrument. J Autism Dev Disord 41: 447-454 (2010).
11. Horn TF, Wolf G, Duffy S, Weiss S, Keilhoff G, MacVicar BA: Nitric oxide promotes intracellular calcium release from mitochondria in striatal neurons. FASEB J 16: 1611-1622 (2002). (Pubitemid 35154644)
12. Hortelano S, Dallaporta B, Zamzami N, Hirsch T, Susin SA, et al: Nitric oxide induces apoptosis via triggering mitochondrial permeability transition. FEBS Lett 410: 373-377 (1997). (Pubitemid 27304099)
13. James SJ, Rose S, Melnyk S, Jernigan S, Blossom S, et al: Cellular and mitochondrial glutathione redox imbalance in lymphoblastoid cells derived from children with autism. FASEB J 23: 2374-2383 (2009).
14. Kollegger H, McBean GJ, Tipton KF: Reduction of striatal N-methyl-D-aspartate toxicity by inhibition of nitric oxide synthase. Biochem Pharmacol 45: 260-264 (1993). (Pubitemid 23023765)
15. Maezawa I, Jin LW: Rett syndrome microglia damage dendrites and synapses by the elevated release of glutamate. J Neurosci 30: 5346-5356 (2010).
16. McGee AM, Baines CP: Complement 1q binding protein inhibits the mitochondrial permeability transition pore and protects against oxidative stress-induced death. Biochem J 433: 119-125 (2010).
17. Meguid NA, Dardir AA, Abdel-Raouf ER, Hashish A: Evaluation of oxidative stress in autism: defective antioxidant enzymes and increased lipid peroxidation. Biol Trace Elem Res (2010). Epub ahead of print.
18. Mostafa GA, El-Hadidi ES, Hewedi DH, Abdou MM: Oxidative stress in Egyptian children with autism: relation to autoimmunity. J Neuroimmunol 219: 114-118 (2010).
19. Palmieri L, Persico AM: Mitochondrial dysfunction in autism spectrum disorders: Cause or effect? Biochim Biophys Acta 1797: 1130-1137 (2010).
20. Pastural E, Ritchie S, Lu Y, Jin W, Kavianpour A, et al: Novel plasma phospholipid biomarkers of autism: mitochondrial dysfunction as a putative causative mechanism. Prostaglandins Leukot Essent Fatty Acids 81: 253-264 (2009).
21. Patterson PH: Modeling autistic features in animals. Pediatr Res 69(5 Pt 2):34R-40R (2011).
22. Schinder AF, Olson EC, Spitzer NC, Montal M: Mitochondrial dysfunction is a primary event in glutamate neurotoxicity. J Neurosci 16: 6125-6133 (1996). (Pubitemid 26313988)
23. Sweeten TL, Posey DJ, Shankar S, McDougle CJ: High nitric oxide production in autistic disorder: a possible role for interferon-gamma. Biol (Pubitemid 38199995)